Palvella Therapeutics, Inc. (PVLA) Enterprise Value (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Enterprise Value for 12 consecutive years, with -$14.2 million as the latest value for Q3 2024.
- On a quarterly basis, Enterprise Value rose 74.95% to -$14.2 million in Q3 2024 year-over-year; TTM through Sep 2024 was -$14.2 million, a 74.95% increase, with the full-year FY2023 number at -$16.3 million, up 72.42% from a year prior.
- Enterprise Value was -$14.2 million for Q3 2024 at Palvella Therapeutics, up from -$14.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$6.2 million in Q1 2024 to a low of -$119.1 million in Q2 2021.
- A 5-year average of -$62.4 million and a median of -$66.8 million in 2021 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: plummeted 100.07% in 2022, then skyrocketed 89.05% in 2024.
- Palvella Therapeutics' Enterprise Value stood at -$70.4 million in 2020, then plummeted by 67.19% to -$117.8 million in 2021, then surged by 49.76% to -$59.2 million in 2022, then soared by 72.42% to -$16.3 million in 2023, then rose by 12.95% to -$14.2 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's Enterprise Value are -$14.2 million (Q3 2024), -$14.5 million (Q2 2024), and -$6.2 million (Q1 2024).